Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Mitomycin for Injection, USP, in 5 mg per vial in a single-dose vial, 20 mg per vial in a single-dose vial, and 40 mg per vial in a single-dose vial.
Meitheal will offer Mitomycin for Injection, USP in a pack of 1 vial for all 3 presentations.
ABOUT MITOMYCIN FOR INJECTION, USP
Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. It is not recommended to replace appropriate surgery and/or radiotherapy. For full prescribing and safety information, please click on the following links (5mg & 20mg PI and 40 mg PI).
Learn more about Mitomycin for Injection, USP
